| The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018 | 822 | 2018 |
| Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade W Abida, ML Cheng, J Armenia, S Middha, KA Autio, HA Vargas, ... JAMA oncology 5 (4), 471-478, 2019 | 569 | 2019 |
| Tumour lineage shapes BRCA-mediated phenotypes P Jonsson, C Bandlamudi, ML Cheng, P Srinivasan, SS Chavan, ... Nature 571 (7766), 576-579, 2019 | 351 | 2019 |
| Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions ML Cheng, E Pectasides, GJ Hanna, HA Parsons, AD Choudhury, ... CA: A Cancer Journal for Clinicians, 2020 | 147 | 2020 |
| Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L) 1 immune checkpoint inhibition in non-small cell lung cancer B Ricciuti, G Recondo, LF Spurr, YY Li, G Lamberti, D Venkatraman, ... Clinical Cancer Research, 2020 | 118 | 2020 |
| Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC) B Ricciuti, G Jones, M Severgnini, JV Alessi, G Recondo, M Lawrence, ... Journal for immunotherapy of cancer 9 (3), 2021 | 106 | 2021 |
| Effects of RANKL-targeted therapy in immunity and cancer ML Cheng, L Fong Frontiers in oncology 3, 329, 2014 | 93 | 2014 |
| The incidence of oesophageal cancer in Eastern Africa: identification of a new geographic hot spot? ML Cheng, L Zhang, M Borok, E Chokunonga, C Dzamamala, A Korir, ... Cancer epidemiology 39 (2), 143-149, 2015 | 77 | 2015 |
| SMARCA4 and other SWItch/Sucrose nonfermentable family genomic alterations in NSCLC: clinicopathologic characteristics and outcomes to immune checkpoint inhibition JV Alessi, B Ricciuti, LF Spurr, H Gupta, YY Li, C Glass, M Nishino, ... Journal of Thoracic Oncology 16 (7), 1176-1187, 2021 | 75 | 2021 |
| Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation A Sacher, P LoRusso, MR Patel, WH Miller Jr, E Garralda, MD Forster, ... New England Journal of Medicine 389 (8), 710-721, 2023 | 74 | 2023 |
| Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC). JK Rotow, DB Costa, CP Paweletz, MM Awad, P Marcoux, D Rangachari, ... Journal of Clinical Oncology 38 (15_suppl), 9507-9507, 2020 | 37 | 2020 |
| Clinical tumour sequencing for precision oncology: time for a universal strategy ML Cheng, MF Berger, DM Hyman, DB Solit Nature Reviews Cancer 18 (9), 527-528, 2018 | 37 | 2018 |
| Abiraterone acetate for the treatment of prostate cancer CJ Ryan, ML Cheng Expert opinion on pharmacotherapy 14 (1), 91-96, 2013 | 35 | 2013 |
| Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients DWY Tsui, ML Cheng, M Shady, JL Yang, D Stephens, H Won, ... Genome medicine 13 (1), 1-15, 2021 | 33 | 2021 |
| Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas JM Sands, T Nguyen, P Shivdasani, AG Sacher, ML Cheng, RS Alden, ... Lung Cancer 140, 35-41, 2020 | 30 | 2020 |
| Report of the first international symposium on NUT carcinoma CA French, ML Cheng, GJ Hanna, SG DuBois, NG Chau, CL Hann, ... Clinical Cancer Research 28 (12), 2493-2505, 2022 | 28 | 2022 |
| Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab MA Postow, SD Chasalow, D Kuk, KS Panageas, ML Cheng, J Yuan, ... Melanoma Research 30 (1), 71-75, 2020 | 25 | 2020 |
| OA03. 04 phase IA study to evaluate GDC-6036 monotherapy in patients with non-small cell lung cancer (NSCLC) with KRAS G12C mutation A Sacher, MR Patel, WH Miller, J Desai, E Garralda, S Bowyer, TW Kim, ... Journal of Thoracic Oncology 17 (9), S8-S9, 2022 | 22 | 2022 |
| Does TMB impact the effectiveness of TKIs in EGFR-mutant NSCLC? ML Cheng, GR Oxnard Clinical Cancer Research 25 (3), 899-900, 2019 | 20 | 2019 |
| Beyond sipuleucel-T: immune approaches to treating prostate cancer ML Cheng, L Fong Current treatment options in oncology 15 (1), 115-126, 2014 | 20 | 2014 |
